UBS Group Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND)

Research analysts at UBS Group assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $196.00 price target on the biotechnology company’s stock. UBS Group’s price target would suggest a potential upside of 45.80% from the stock’s previous close.

Several other brokerages have also recently commented on ASND. The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of ASND opened at $134.43 on Tuesday. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The firm has a fifty day simple moving average of $132.30 and a 200 day simple moving average of $133.59. The stock has a market capitalization of $8.16 billion, a price-to-earnings ratio of -16.64 and a beta of 0.65.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently bought and sold shares of ASND. Rhumbline Advisers increased its position in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $864,000. First Turn Management LLC raised its holdings in Ascendis Pharma A/S by 23.1% in the 2nd quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock valued at $25,446,000 after buying an additional 34,994 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Ascendis Pharma A/S by 42.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $945,000 after buying an additional 2,048 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after buying an additional 93,185 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.